NCT00169156View on ClinicalTrials.gov

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

November 30, 2012

Conditions
Untreated T-cell Angioimmunoblastic Lymphoma
Interventions
DRUG

Rituximab

375 mg/m2 D1

DRUG

Prednisone

40 mg/m2 D1 to D5

DRUG

Doxorubicine

50 mg/m2 D1

DRUG

Cyclophosphamide

750 mg/m2 D1

DRUG

Vincristine

1,4 mg/m2 D1

Trial Locations (4)

69495

Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite

Unknown

Hôpital Henri Mondor, Créteil

Hôpital Saint Louis, Paris

Centre Henri Becquerel, Rouen

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Lymphoma Study Association

OTHER

NCT00169156 - A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma | Biotech Hunter | Biotech Hunter